NextCell Pharma Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda NextCell Pharma için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi	48.7%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

May 31

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Feb 15

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak NextCell Pharma yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

OM:NXTCL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (SEK Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
8/31/2024	11	-42	-38	-38	N/A
5/31/2024	14	-37	-43	-43	N/A
2/29/2024	15	-39	-48	-46	N/A
11/30/2023	16	-41	-49	-45	N/A
8/31/2023	14	-40	-48	-44	N/A
5/31/2023	11	-40	-45	-33	N/A
2/28/2023	9	-38	-41	-32	N/A
11/30/2022	8	-37	-44	-36	N/A
8/31/2022	6	-35	-41	-33	N/A
5/31/2022	6	-30	-37	-37	N/A
2/28/2022	6	-28	-33	-33	N/A
11/30/2021	5	-26	-27	-26	N/A
8/31/2021	4	-25	-26	-26	N/A
5/31/2021	4	-25	-26	-25	N/A
2/28/2021	4	-23	-23	-23	N/A
11/30/2020	4	-19	-21	-20	N/A
8/31/2020	4	-18	-20	-19	N/A
5/31/2020	4	-17	-18	-16	N/A
2/29/2020	4	-17	-18	-17	N/A
11/30/2019	3	-16	-16	-16	N/A
8/31/2019	2	-18	-19	-19	N/A
5/31/2019	2	-17	-21	-21	N/A
2/28/2019	1	-15	-17	-17	N/A
11/30/2018	1	-16	-17	-17	N/A
8/31/2018	1	-14	-14	-14	N/A
5/31/2018	1	-15	N/A	-15	N/A
2/28/2018	1	-16	N/A	-17	N/A
11/30/2017	1	-14	N/A	-15	N/A
8/31/2017	1	-13	N/A	-15	N/A
5/31/2017	1	-11	N/A	-11	N/A
2/28/2017	1	-10	N/A	-10	N/A
11/30/2016	1	-11	N/A	-11	N/A
8/31/2016	1	-11	N/A	-11	N/A
8/31/2015	0	-7	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NXTCL 'un tahmini kazanç büyümesinin tasarruf oranının ( 1.1% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: NXTCL 'un kazançlarının Swedish pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: NXTCL şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: NXTCL şirketinin gelirinin Swedish pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: NXTCL şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NXTCL 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

NextCell Pharma Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Full year 2024 earnings released: kr1.22 loss per share (vs kr1.16 loss in FY 2023)

NextCell Pharma AB to Report Q1, 2025 Results on Jan 30, 2025

NextCell Pharma AB Announces Drug Candidate ProTrans Highlighting in Dagens Medicin's Latest Edition Featuring Ongoing Research Advances in the Treatment of Type 1 Diabetes

NextCell Pharma AB Announces the First Children Have Been Treated in the Young Age Group of the ProTrans-Young Study

NextCell Pharma AB Presents New Long-Term Clinical Data at the International Society for Cell and Gene Therapy 2024 Regional Meeting

Third quarter 2024 earnings released

New major risk - Shareholder dilution

Nextcell Pharma AB Receives Positive Recommendation from Data Safety Monitoring Board for Protrans-Young Study

Nextcell Pharma AB Elects Hans-Peter Ekre as New Chairman of the Board

Second quarter 2024 earnings released

NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue

NextCell Pharma AB, Annual General Meeting, Nov 28, 2024

Anders Essen-Möller Resigns as Chairman of NextCell Pharma AB

The Swedish Medical Products Agency Approves Subgroup Analysis in NextCell Pharma AB's ProTrans-Young study

New minor risk - Share price stability

First quarter 2024 earnings released

Nextcell Pharma Announces Updates Regarding Nextcell's Clinical Trials with Protrans

Full year 2023 earnings released

NextCell Pharma AB to Report Fiscal Year 2024 Results on Oct 24, 2024

Third quarter 2023 earnings released

NextCell Pharma AB Announces Treatment Start of Severe Pneumonia with High Dose of ProTrans

New minor risk - Share price stability

Second quarter 2023 earnings released

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

First quarter 2023 earnings released

NextCell Pharma AB to Report Fiscal Year 2023 Final Results on Nov 09, 2023

NextCell Pharma AB Announces First Pediatric Patients Treated with ProTrans in Type-1 Diabetes Phase II Study

Less than half of directors are independent

Full year 2022 earnings released

Nextcell Pharma AB Announces Trial with Protrans Gets Green Light for Phase Ii Part

Nextcell Cell Therapy Shows Long-Term Effect in Two Independent Diabetes Studies "ProTrans-Repeat" and "ProTrans-Obs"- Live Presentation

Nextcell Pharma AB Announces Protrans Cell Therapy Provides Long-Term Effect in Type-1 Diabetes with A Single Treatment

NextCell Pharma AB Announces Type-1 Diabetes Patients Receiving Two Treatments with A High Dose of Protrans Cell Therapy

We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

NextCell Pharma AB Announces ProTrans Cell Therapy to Be Granted Patent Protection Beyond Europe

Third quarter 2022 earnings released

NextCell Pharma AB Announces Patients in the First Part of Pediatric Diabetes Trial with Nextcell's Protrans Treated

The European Patent Office intends to grant a Patent to NextCell Pharma AB for Selection Algorithm

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

Second quarter 2022 earnings released

Less than half of directors are independent

NextCell Pharma AB Announces First Age Group Treated in Paediatric Diabetes Study with Protrans

NextCell Pharma AB Announces Clinical Trial ProTrans19+CA Expanded to Include an Additional Site: The Jewish General Hospital In Montreal, Canada

NextCell Pharma AB Announces Pediatric Diabetes Study with ProTrans in Progress

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings: Revenues in line with analyst expectations

NextCell Pharma AB to Report Fiscal Year 2022 Final Results on Nov 03, 2022

Director recently bought kr61k worth of stock

We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Third quarter 2021 earnings released

NextCell Pharma AB Announces COVID-19 Patient Treated with ProTrans

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

NextCell Presents Their Latest Phase II Clinical Data at ISCT 2021

NextCell Pharma AB Announces That Both the Canadian and Swedish Covid-19 Studies Have Been Initiated and Are Now Ready to Include Patients with Severe Pneumonia Triggered by Sars-Cov-2 Infection

Nextcelpharmama AB Recruitments Start for the Protrans Study for Treatment of Covid-19

Second quarter 2021 earnings released

New 90-day low: kr15.30

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

NextCell Pharma AB Announces Canadian Trial for ProTrans in COVID-19

First quarter 2021 earnings released: kr0.23 loss per share (vs kr0.20 loss in 1Q 2020)

New 90-day low: kr16.15

NextCell Pharma AB, Annual General Meeting, Nov 24, 2021

New 90-day low: kr16.80

Nextcell Pharma AB Announces Observational Study, Protrans-Obs, receives Approval by the Swedish Ethical Review Board

New 90-day low: kr18.30

NextCell Pharma AB Supports ProTrans Study for Children and Adolescents

Nextcell Starts Eurostars Funded Project Bioscale

Full year earnings released - kr0.92 loss per share

New 90-day high: kr23.80

New 90-day high - kr19.40

NextCell Pharma AB to Report Fiscal Year 2020 Final Results on Nov 12, 2020

New 90-day high - kr13.30

NextCell Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 25.100028 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri